Next Science Beheer

Beheer criteriumcontroles 0/4

De CEO Next Science is I.V. Hall, benoemd in Jul2023, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 418.38K, bestaande uit 47.6% salaris en 52.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.23% van de aandelen van het bedrijf, ter waarde A$ 103.10K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 1.3 jaar.

Belangrijke informatie

I.V. Hall

Algemeen directeur

US$418.4k

Totale compensatie

Percentage CEO-salaris	47.6%
Dienstverband CEO	1.3yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	1.3yrs

Recente managementupdates

Recent updates

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Oct 22

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Jul 26

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

Jun 08

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Apr 16

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Mar 06

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Dec 26

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Oct 26

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

May 13

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Feb 03

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Jan 25

What Type Of Returns Would Next Science's(ASX:NXS) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Nov 23

Analyse CEO-vergoeding

Hoe is I.V. Hall's beloning veranderd ten opzichte van Next Science's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$14m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$418k	US$199k	-US$16m

Compensatie versus markt: De totale vergoeding ($USD 418.38K ) I.V. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 304.34K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van I.V. te vergelijken met de prestaties van het bedrijf.

CEO

I.V. Hall

1.3yrs

Tenure

US$418,378

Compensatie

Mr. Harry Thomas Hall, IV, also known as I.V., has been Managing Director and Chief Executive Officer at Next Science Limited since July 10, 2023. He serves as Director at Next Science Limited since July 1...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Harry Hall	MD, CEO & Director	1.3yrs	US$418.38k	0.23% A$ 103.1k
Matthew Myntti	Founder & CTO	no data	US$413.71k	1.43% A$ 646.6k
Marc Zimmerman	Chief Financial Officer	1.5yrs	US$343.34k	0.051% A$ 23.2k
Jon Swanson	Chief Operating Officer	6.4yrs	US$298.60k	0.017% A$ 7.7k
Robert Bell	Senior Vice President of North American Sales	less than a year	geen gegevens	geen gegevens
Gillian Nairn	Company Secretary	6.4yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

Ervaren management: Het managementteam van NXS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Harry Hall	MD, CEO & Director	1.3yrs	US$418.38k	0.23% A$ 103.1k
Grant Hummel	Independent Non-Executive Director	1.3yrs	US$21.45k	0.13% A$ 60.1k
Aileen Stockburger	Independent Non-Executive Chairman	6.1yrs	US$111.85k	0.19% A$ 88.3k
Katherine Ostin	Independent Non-Executive Director	1.1yrs	US$12.66k	geen gegevens

1.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van NXS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.

Next Science Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Next Science Limited, Annual General Meeting, May 03, 2024

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

Next Science Limited Announces Executive Changes

Founder & CTO recently sold AU$1.5m worth of stock

Recent updates

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper

Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024

Consensus EPS estimates fall by 11%

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce

Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024

Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024

It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks

New minor risk - Share price stability

Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024

Will Next Science (ASX:NXS) Spend Its Cash Wisely?

Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce

Next Science Limited, Annual General Meeting, May 03, 2024

Full year 2023 earnings released: US$0.069 loss per share (vs US$0.06 loss in FY 2022)

Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk

Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.

Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%

Consensus revenue estimates decrease by 10%

Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director

Consensus revenue estimates increase by 26%, EPS downgraded

New minor risk - Shareholder dilution

First half 2023 earnings released: US$0.04 loss per share (vs US$0.032 loss in 1H 2022)

New minor risk - Financial data availability

Next Science Limited Announces Board Changes

Next Science Limited Appoints Marc Zimmerman as Chief Financial Officer

New minor risk - Share price stability

Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products

Next Science Limited Announces Executive Changes

Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper

Founder & CTO recently sold AU$1.5m worth of stock

Consensus EPS estimates fall from profit to US$0.051 loss, revenue upgraded

Full year 2022 earnings released: US$0.06 loss per share (vs US$0.047 loss in FY 2021)

Next Science Limited, Annual General Meeting, May 26, 2023

The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts

Forecast breakeven date pushed back to 2024

Next Science Limited announced that it expects to receive AUD 10 million in funding from Walker Group Holdings Pty Limited

Insufficient new directors

Next Science Limited Announces the Launch of Topical Collagen Products

Next Science Limited Announces Health Canada Given Licensing Approval for XPERIENCE

First half 2022 earnings released: US$0.032 loss per share (vs US$0.021 loss in 1H 2021)

Forecast breakeven date pushed back to 2024

Next Science Limited to Report First Half, 2022 Results on Aug 25, 2022

Consensus forecasts updated

Next Science Limited's Judith Mitchell to Step Down as Chief Executive Officer

Insufficient new directors

MD, CEO & Executive Director recently sold AU$123k worth of stock

Next Science Limited, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation

Insufficient new directors

Founder & CTO recently sold AU$8.6m worth of stock

First half 2021 earnings released: US$0.021 loss per share (vs US$0.037 loss in 1H 2020)

Next Science Limited Agrees to Open Negotiations with Zimmer, Inc

Next Science Limited Provides Revenue Guidance for the First Half of 2021

Next Science Limited Receives Approval for BlastX from Therapeutic Goods Administration for Sale in Australia

Independent Non-Executive Chairman George Savvides has left the company

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Next Science Limited Announces XPerience No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Independent Non-Executive Director recently sold AU$564k worth of stock

MD, CEO & Executive Director exercised options to buy AU$2.5m worth of stock.

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future

Next Science Limited, Annual General Meeting, May 05, 2021

Analysts update estimates

Full year 2020 earnings released: US$0.064 loss per share (vs US$0.086 loss in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day high: AU$1.38

Here's Why We're Watching Next Science's (ASX:NXS) Cash Burn Situation